StockNews.AI
RCKT
StockNews.AI
62 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT

1. Pomerantz LLP investigates claims against Rocket Pharmaceuticals for securities fraud. 2. Rocket paused dosing of RP-A501 after a patient experienced severe complications. 3. FDA placed a clinical hold on RP-A501 trial due to serious adverse events. 4. Rocket's stock fell 62.84% to $2.33 following the adverse event news. 5. Investors are urged to contact Pomerantz regarding potential class actions.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Significant drop in stock price following negative trial results indicates investor loss of confidence.

How important is it?

The majors issues raised in the article directly threaten RCKT's operational credibility and stock value.

Why Short Term?

Immediate reactions to the news showcase market's sensitivity to adverse trial outcomes.

Related Companies

ZGNXCRSPBLDP
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Rocket and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 27, 2025, Rocket issued a press release “announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.”  The press release disclosed that “[a] patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE)” that “involved clinical complications related to a capillary leak syndrome.”  The press release said that “[u]pon learning of the initial event, Rocket voluntarily paused further dosing in the study” and that “[o]n May 23, 2025, the FDA placed a clinical hold on the trial to allow for further evaluation.”  Finally, the press release noted that the patient in question “has since passed away after an acute systemic infection.”  On this news, Rocket’s stock price fell $3.94 per share, or 62.84%, to close at $2.33 per share on May 27, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.    CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News